Fourth BBBNedwork meeting

Friday 18 March 2016,  10.30 - 18.00; Biopartner Auditorium, J.H. Oortweg 19, Leiden Bioscience Park

10.00 - 10.30  

Registration and Coffee

 10.30 - 10.45  

Welcome and introduction new partners

10.45 - 11.00  
Inge Zuhorn (UMCG) Development of vectors for gene deivery to the central nervous system
11.00 - 11.15
Heli Savolainen (UMCG), PET imaging of functional P-gp in rats – diurnal fluctuations and sleep deprivation
 11.15 - 11.30  
Nienke de Wit (VUmc),  Role of nuclear receptors in BBB function

11.30 - 12.15 

Keynote: Prof. dr. Peter de Boer (Johnson & Johnson) Translation of animal data to the clinic: challenges in psychiatric drug development

12.15 - 13.15

Lunch and break out sessions

13.15 - 13.45  

Dr. Pieter Gaillard (2 BBB) and dr. Eric Ronken (DII BV),  Future of scientist in industry – career management

 13.45 - 14.15  

Dr. Morola Lipzig (TNO), Quantification of ABC transporter protein expression in rat brain with LC-MS

14.15 - 14.45
Dr. Matthias J.P. van Osch (LUMC), Imaging of subtle BBB-damage by MRI
14.45 - 15.00
Tea time

15.00 - 15.15 

Anne-Eva van Wijk  (AMC), TNFa and cAMP in blood-retinal barrier

15.15 - 15.30  
Dr. Erwin van Vliet (AMC), Anatoly Korotkov; Extracellular matrix molecules and modulation by miRNAs in epilepsy
15.30 - 16.00   Prof. dr. Bart van Berckel (Vumc), PET imaging of ABC transporters at the BBB in Alzheimer’s disease

16.00 - 18.00

Closing remarks and Drinks

 

 


Third BBBNedwork meeting

Friday 20 March 2015, 10.30 - 16.30 ; Biopartner Auditorium, J.H. Oortweg 19, Leiden Bioscience Park

Participant information slides (2015) & Photos from the 2015 meeting

10.00 - 10.30 

Registration and Coffee

10.30

Welcome and introduction

  Valeria Orlova (LUMC) – Modeling of neurovascular diseases with human induced pluripotent stem cells
  Claudio Derada Troletti(MCBI, VUmc) - Molecular control of the BBB
  Marinke van der Helm (BIOS Lab on a Chip, TU) A microfluidic platform to study and modulate the blood-brain barrier

 

Keynote: Dr. Matthew Campbell (Trinity College, Dublin, Ireland) - RNAi-mediated modulation of the BBB; from basic to apllied science.

12.30 - 14.00

Lunch and break out sessions

 

Roundtable discussions
A. In vitro models for barriers of the CNS (chairs Inge Zuhorn UMCG/ Ingeborg Klaassen AMC)
B. In vivo imaging (chair Gert Luurtsema UMCG)
C. In vivo modellen available in consortium with impaired BBB (chairs Olaf van Tellingen NKI / Erwin van Vliet AMC)

14.00

Reinier Schlingemann (Ophthalmology, AMC) – PLVAP at the BRB/BBBThe role of PLVAP in regulating vascular permeability and angiogenesis-relevance for the blood-brain and blood-retinal barriers

  Lisanne van Leeuwen (Medical Microbiology, VUmc) Mycobacterium marinum can cross the blood-brain barrier via different migration routes
  Tonny Lageweij (Neuro-oncology, VUmc) – 3D imaging and modeling of the brain vasculature

 

Diewertje Bink (Pathology, AMC) – Intracranial atherosclerosis, cholesterol and the BBB

  Gert Luurtsema (UMCG, Groningen) - PET imaging of ABC transporters at the BBB; where are we now?

15.45

Closing remarks and Drinks

 

 


Second BBBNedwork meeting

Friday 21 March 2014, 10.30 - 16.3010.30 - 16.30 ; Leiden Bioscience Park

Information slides of participants at the BBBNedwork meetings

A Photo Impression (for all photos see picasa):

 

 

Program 

10.00 – 10.3010.00 – 10.30 

Registration and Coffee

10.30 

Welcome and introduction

 

Erwin van Vliet, Center for Neuroscience, Swammerdam Institute for Life Sciences, UvA, Amsterdam. Sequential magnetic resonance imaging after status epilepticus reveals differential effects of rapamycin on blood-brain barrier function in the rat

 

Renske Raaphorst, Department of Radiology & Nuclear Medicine, VUmc, Amsterdam. Evaluation of a new fluorine-18 labelled verapamil analogue for investigating P-gp function 

 

Laura Kervezee, Laboratory of Neurophysiology, Department of Molecular Cell Biology, LUMC and Division of Pharmacology, LACDR, Leiden. Diurnal variation in P-glycoprotein mediated transport and cerebrospinal fluid turnover in the central nervous system

 

Keynote: Perry Calias, Shire, Boston, US. Intrathecal Delivery of Protein Therapeutics to the Brain: A Critical Reassessment. 

12.15 – 14.15

Lunch break & roundtable discussions

  Business Meeting to discuss the future of BBBNedwork

 

Mark Mizee, Department of Molecular Cell Biology and Immunology, Neuroscience Campus Amsterdam, VUmc, Amsterdam. Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function during neuroinflammation in multiple sclerosis.

 

Joanna Wisniewska-Kruk, Ocular Angiogenesis Group, Department of Ophthalmology and Cell Biology and Histology, AMC, UvA, Amsterdam. The role of plasmalemma vesicle-associated protein in blood retinal barrier permeability  

 

David Maussang, to-BBB technologies BV, Leiden. Glutathione PEGylated liposomes: unraveling the mechanism for enhanced drug delivery to the brain

 

Mieke de Jager, Department of Anatomy and Neurosciences, Cellular Neuropharmacology section, Neuroscience Campus Amsterdam, VUMc, Amsterdam. The blood-derived transglutaminase Factor XIII colocalises with Aβ deposition in cerebral amyloid angiopathy and forms complexes with Aβ in vitro

 

Patrick de Boer, ttopstart, Bilthoven. Grant writing

 

Closing remarks

16.15 

Drinks

Roundtable discussions (25 minutes)

1.       Patent and/or Publish?! (Pieter Gaillard, to-BBB technologies BV, Leiden)
Similarities and differences between academic and company research

2.       Top models (Liesbeth de Lange, Division of Pharmacology, LACDR, Leiden)
Use of models to understand relationships between multiple parameters.

3.       Crossing barriers (Arie Reijerkerk, to-BBB technologies BV, Leiden)
Extending blood-brain barrier research to the eye

4.       Imagination (Elga de Vries, Department of Molecular Cell Biology and Immunology, Neuroscience Campus Amsterdam, VUmc, Amsterdam and Bert Windhorst, Department of Radiology & Nuclear Medicine, VUmc, Amsterdam)
Visualize BBB dynamics using imaging techniques 

Keynote Speaker: Dr. Perry Calias

Perry Calias specializes in the development of targeted therapies. As Senior Director for Shire HGT, he has championed the investigational effort for the intrathecal administration of recombinant enzymes for the treatment of the CNS manifestations associated with lysosomal diseases. In this capacity, he has led the research effort with regards to regulatory filings both within the US and abroad resulting in 3 clinical trials and several peer-reviewed articles. He has held various R&D positions at EyeGate Pharmaceuticals (Vice President, Research and Development), Eyetech Pharmaceuticals (Senior Director, Drug Delivery/Chemistry) and Draper Laboratories (Senior Technical Lead), and Genzyme Corporation (Senior Scientist, Biomaterials and Surgical Products Research Department). Dr. Calias is listed as an inventor on over 30 domestic and foreign patents/applications spanning 18 different patent families, including mRNA therapeutics, new polyethylene glycol-linker chemistries, noninvasive ocular delivery devices, nucleic acid-protecting strategies, and combination anti-angiogenic therapies. He obtained his Ph.D. in Bio-Organic Chemistry in 1996 and his M.S. in 1993 from Tufts University.

BBBNedwork kick-off meeting

Friday 22 March 2013, Leiden

Introduction slides of participants and speakers at the BBBNedwork kick-off meeting 22 March 2013

A photo impression:

 

Program 

9.30 – 10.00

Registration and Coffee

10.00 – 10.1010.00 – 10.10    

Introduction BBBNedwork

10.10 – 11.0010.10 – 11.00 

Introduction participants

11.00 – 11.15

Elga de Vries, Blood-Brain Barrier Research group, VUmc, Amsterdam
The neurovascular unit in health and disease; implications for multiple sclerosis

11.15 – 11.30

Inge Zuhorn, Cell Biology-Membrane Cell Biology, UMCG, Groningen
Targeted nanoparticles to the blood-brain barrier 

11.30 – 12.15

Keynote: Joan Abbott, King’s College, Londen, UK 
Snap, zip, crackle and pop: the blood-brain barrier, neuroscience and CNS drug delivery

12.15 – 14.15

Lunch break & visit to-BBB labs

14.15 – 14.30

Rick Dijkhuizen, Biomedical MR Imaging & Spectroscopy group, UMCU, Utrecht
MRI of neurovascular changes in neurological disease models

14.30– 14.45

Liesbeth de Lange, Division of Pharmacology, LACDR, Leiden
Towards prediction of the effects of CNS drugs in human: the role of the BBB 

14.45 – 15.00

Louise van der Weerd, Functional and Molecular MR group, LUMC, Leiden 
The BBB in neurodegenerative diseases: mighty fortress or crumbling walls 

15.00 – 15.15

William Leenders, Department of Pathology, Radboud UNMC, Nijmegen 
Anti-angiogenic therapy for brain tumors: a terrible dilemma  

15.15 – 15.30

Reinier Schlingemann, Medical Retina Unit and Ocular angiogenesis group, AMC, Amsterdam 
The blood-retinal barrier in health and disease 

15.30 – 16.00

Adriaan Lammertsma, Department of Radiology & Nuclear Medicine, Radionuclidencentrum, Amsterdam 
Non-invasive assessment of the blood-brain barrier using positron emission tomography 

16.00 – 16.15

Closing remarks

16.15

Drinks